Tag Archives: Dual-Agonist
Retatrutide vs. Tirzepatide Research: A Comparative Analysis of Molecular Agonism
In the TRIUMPH-1 Phase 3 study, retatrutide demonstrated an average weight reduction of 28% over 80 weeks, a benchmark that resets expectations for...
